A prospective randomized trial of HLA-matched versus mismatched single-donor platelet transfusions in cancer patients
Gerald L. Messerschmidt(University of Michigan–Ann Arbor), Albert Deisseroth(National Cancer Institute), Nicholas P. Anagnou(National and Kapodistrian University of Athens), Richard S. Ungerleider(Unknown), Joseph A. Fontana(Michigan United), Ting Shan(National Cancer Institute), Ross A. Abrams(Rush University Medical Center), Thomas V. Holohan(National Cancer Institute), Robert Makuch(Kazimierz Pułaski University of Technology and Humanities in Radom), Daniel G. Wright(University of Washington), F R Appelbaum(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Joseph O'Donnell(National Cancer Institute), Byron Chesbro(National Cancer Institute)
Cited by 27
Related Papers
Uniform approach to risk classification and treatment assignment for children with acute lymphoblastic leukemia.
|Journal of Clinical Oncology|1996|914
High-Dose Melphalan and Autologous Stem-Cell Transplantation in Patients with AL Amyloidosis: An 8-Year Study
|Annals of Internal Medicine|2004|615
How Sociodemographics, Presence of Oncology Specialists, and Hospital Cancer Programs Affect Accrual to Cancer Treatment Trials
|Journal of Clinical Oncology|2002|531
Unilateral Transplantation of Human Fetal Mesencephalic Tissue into the Caudate Nucleus of Patients with Parkinson's Disease
|New England Journal of Medicine|1992|516